Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Has Average Target Price of $41.80

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $41.80.

SNDX has been the subject of a number of research reports. JPMorgan Chase & Co. dropped their price objective on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Bank of America reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. UBS Group restated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Thursday, October 1st. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, September 29th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Arizona State Retirement System boosted its holdings in Syndax Pharmaceuticals by 2.9% in the second quarter. Arizona State Retirement System now owns 23,120 shares of the company’s stock valued at $505,000 after purchasing an additional 642 shares in the last quarter. Wellington Management Group LLP raised its holdings in Syndax Pharmaceuticals by 0.5% during the second quarter. Wellington Management Group LLP now owns 124,241 shares of the company’s stock worth $2,716,000 after purchasing an additional 655 shares in the last quarter. Hsbc Holdings PLC raised its holdings in Syndax Pharmaceuticals by 3.2% during the first quarter. Hsbc Holdings PLC now owns 23,461 shares of the company’s stock worth $556,000 after purchasing an additional 730 shares in the last quarter. Allworth Financial LP acquired a new stake in Syndax Pharmaceuticals during the second quarter worth approximately $26,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Syndax Pharmaceuticals by 11.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 19,564 shares of the company’s stock worth $467,000 after buying an additional 2,002 shares during the last quarter.

Syndax Pharmaceuticals News Summary

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Analysts see potential recovery: BofA Securities said the selloff following the trial failure appears “overdone,” while HC Wainwright reaffirmed its Buy rating and maintained a $38 price target. These views suggest analysts believe Syndax’s remaining pipeline and cGVHD opportunity retain substantial value. BofA Securities says Syndax selloff appears overdone
• Neutral Sentiment: Axatilimab was well tolerated: Syndax reported no new safety signals in the MAXPIRe Phase 2 trial, with a safety profile comparable to placebo. The drug is continuing to advance in multiple cGVHD studies, with additional results expected later this year and in early 2028. Syndax MAXPIRe trial topline results
• Negative Sentiment: MAXPIRe missed its primary endpoint: The Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed to demonstrate a reduction in the annualized rate of decline in forced vital capacity, a key measure of lung-function deterioration. Syndax ended development of the program in IPF, eliminating a potential growth opportunity and triggering the sharp selloff. Syndax MAXPIRe trial misses primary endpoint

Syndax Pharmaceuticals Trading Down 15.7%

Shares of NASDAQ SNDX opened at $13.95 on Friday. The company has a debt-to-equity ratio of 38.95, a current ratio of 6.77 and a quick ratio of 6.44. Syndax Pharmaceuticals has a 52-week low of $12.99 and a 52-week high of $25.59. The business’s 50 day moving average is $18.88 and its two-hundred day moving average is $20.40.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). Syndax Pharmaceuticals had a negative return on equity of 372.94% and a negative net margin of 87.52%. The firm had revenue of $72.79 million for the quarter, compared to analyst estimates of $79.36 million. During the same quarter last year, the company earned ($0.83) earnings per share. The firm’s revenue for the quarter was up 91.8% on a year-over-year basis. As a group, equities research analysts predict that Syndax Pharmaceuticals will post -2.03 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax’s lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older.